News
Despite two decades of clinical experience with Everolimus in transplant medicine, cancer patients continue to face ...
START and OneOncology are launching three new early-phase cancer trial sites in California, Texas, and New Jersey, expanding access in community settings where 70% of patients receive care.
IMUNON’s Phase 2 OVATION 2 trial of IMNN-001 in advanced ovarian cancer showed a 13-month OS increase (46 vs. 33 months) and ...
ONCOLife presents an exclusive interview with Sarah Hein, CEO of March Biosciences. In this session, we explore clinical ...
ONCOLife presents an exclusive interview with Nick Slack, Chairman and CEO of The START Center for Cancer Research. In this session, we explore how the integration of the Carolina Urologic Research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results